Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site.

My Top 3 ASX Healthcare Shares… And CSL Ltd

Forget CSL shares, Cochlear Ltd (ASX: COH), Nanosonics Ltd (ASX:NAN) and ResMed Inc (ASX:RMD) shares are amongst my top three ASX healthcare shares.

Cochlear Ltd (ASX: COH), Nanosonics Ltd (ASX: NAN) and ResMed Inc (ASX: RMD) shares are amongst my top three ASX healthcare shares.

Why Healthcare?

I think investing in healthcare companies can provide great long-term returns, as these companies often have a competitive advantage which can help them meaningfully increase profits and cash flow over time.

For example, investors who bought into CSL Ltd (ASX: CSL) when they initially floated on the ASX have seen its valuation rise from just $300 million to $89 billion today. That’s a return of almost 300x — before dividends are included!

Here are three other ASX healthcare companies I like and would consider adding to my portfolio at the right price, should a good opportunity arise.

Cochlear Ltd

As I previously wrote in this Rask Media article, hearing aid marker Cochlear has had a life-changing impact on me personally.

Obviously, I have a vested interest and would like to see them continue to grow their profits. This is because they can continue to upgrade the external processor for people like myself, while also upgrading newer models to assist future recipients.

While Cochlear’s half-year results may be a little disappointing to investors, I am confident that over the long term they can continue to grow their profits.

Resmed Inc

ResMed manufactures continuous positive airway pressure (CPAP) machines. CPAP is considered the gold standard for treating sufferers of sleep apnea. This is a big growth market.

But if we throw in data collection and the likelihood of using artificial intelligence to improve diagnostics and treatment for patients, ResMed’s long-term growth prospects look good.

ResMed’s half-year results disappointed the market, but investors reacted positively to its third-quarter report — highlighting yet again that it’s important to stay focused on the long-term.

Nanosonics Ltd

Nanosonics manufactures the Trophon EPR ultrasound probe disinfector and its related consumables. Trophon saves time and helps to prevent the spread of infections in hospitals.

Investors liked Nanosonics’ half-year report, but it was only six months earlier that investors were clamouring for an exit after the company’s FY18 results.

Again, it’s important to stay focused on the long-term with healthcare shares and ride the dips in share price — or potentially take them as an opportunity to buy more!

[ls_content_block id=”14947″ para=”paragraphs”]

Disclosure: at the time of writing, Andrew does not hold any shares in the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content